Windtreetx

All Photos Twitter.com
909 followers
Today we presented the full data set from our SEISMiC Phase 2 study of #istaroxime in early cardiogenic shock. We met our primary endpoint with a statistically significant difference in how istaroxime treated patients improved and persisted. Full release: bit.ly/3ly26rd
Today at 4:30pm EDT we are hosting a conference call & webcast to discuss #istaroxime Phase 2 positive study results in early cardiogenic shock patients following the late-breaker presentation of the data @escardio #HeartFailure2022 Meeting. To join: bit.ly/3a9t2eq
We'll be hosting a conference call & webcast to discuss #istaroxime Phase 2 positive study results in early cardiogenic shock patients following the late-breaker presentation of the data @escardio #HeartFailure2022 Meeting on 5/23 at 4:30pm EDT. To join: bit.ly/3a9t2eq
“We are extremely pleased with the results of this trial and look forward to a full presentation of the data in the coming weeks,”stated Steve Simonson, M.D., CMO of Windtree. Explore more on our Phase 2 study of istaroxime: bit.ly/3KZsPrR
Yesterday, we announced positive primary results with istaroxime in rapidly raising systolic blood pressure, the critical clinical objective in treating patients in cardiogenic shock. Read more on what CEO, Craig Fraser, had to say about the results: bit.ly/3KZsPrR
Twiends™ uses the Twitter™ API, displays it's logo & trademarks, and is not endorsed or certified by them. These items remain the property of Twitter. We do not sell followers, we only provide display advertising. Bots & fake accounts are not permitted on twiends. © 2009
Grow Your Twitter Free
Want To Grow Your Twitter?
We help other people find and follow you on Twitter.
Key Info:
Started in 2009
Over 6 million signups
Country targeting provided
We never auto tweet to your timeline
We never auto follow others
We actively moderate our community
Please Share
Please upgrade your browser  chrome